--- title: Advancing Healthcare Decision-Making Through Network Meta-Analysis description: It is essential to lay a strong foundation during the start-up phase, which involves conducting the necessary background work from subject recruitment to site selection, as this will affect the trial’s outcome. However, if not carried out effectively, this phase of the trial can be delayed, costing time and money to all parties involved. In […] image: https://clinixir.com/hubfs/Edited%20Photos/Clinix_Blog_03-Thumnail.png --- [![CLX\_Logo-White](https://clinixir.com/hs-fs/hubfs/Logo/CLX_Logo-White.png?width=193&height=40&name=CLX_Logo-White.png "CLX_Logo-White")](https://clinixir.com) [![CLX\_Logo-Default](https://clinixir.com/hs-fs/hubfs/Logo/CLX_Logo-Default.png?width=169&height=35&name=CLX_Logo-Default.png "CLX_Logo-Default")](https://clinixir.com/) - [Services](https://clinixir.com/services) - [Clinical Trial Management](https://clinixir.com/services/clinical-trail) - [Regulatory Affairs](https://clinixir.com/services/regulatory-affairs) - [Sponsor’s Local Representative & IOR Services](https://clinixir.com/services/sponsor-local-representative-ior) - [Pharmacovigilance](https://clinixir.com/services/pharmacovigilance) - [Biometrics](https://clinixir.com/services/biometrics) - [Site Management Organization](https://clinixir.com/services/site-management-organization) - [Real World Evidence](https://clinixir.com/services/real-world-evidence) - [Data ConneX](https://clinixir.com/services/dataconnex) - [About Us](https://clinixir.com/about-us) - [Our Partners](https://clinixir.com/about-us#our-partners) - [Our Vision and Mission](https://clinixir.com/about-us#vision) - [Board of Directors](https://clinixir.com/about-us#board) - [Updates](https://clinixir.com/blog) - [Careers](https://clinixir.com/careers) - [Contact Us](https://clinixir.com/contact-us) - [Partner Site Network](https://clinixir.com/contact-us#partner-site) [Email Us](mailto:enquiries@clinixir.com) [Email Us](mailto:enquiries@clinixir.com) [Email Us](mailto:enquiries@clinixir.com) More results - [Services](https://clinixir.com/services) - [Clinical Trial Management](https://clinixir.com/services/clinical-trail) - [Regulatory Affairs](https://clinixir.com/services/regulatory-affairs) - [Sponsor’s Local Representative & IOR Services](https://clinixir.com/services/sponsor-local-representative-ior) - [Pharmacovigilance](https://clinixir.com/services/pharmacovigilance) - [Biometrics](https://clinixir.com/services/biometrics) - [Site Management Organization](https://clinixir.com/services/site-management-organization) - [Real World Evidence](https://clinixir.com/services/real-world-evidence) - [Data ConneX](https://clinixir.com/services/dataconnex) - [About Us](https://clinixir.com/about-us) - [Our Partners](https://clinixir.com/about-us#our-partners) - [Our Vision and Mission](https://clinixir.com/about-us#vision) - [Board of Directors](https://clinixir.com/about-us#board) - [Updates](https://clinixir.com/blog) - [Careers](https://clinixir.com/careers) - [Contact Us](https://clinixir.com/contact-us) - [Partner Site Network](https://clinixir.com/contact-us#partner-site) [Email Us](mailto:enquiries@clinixir.com) [Case Study](https://clinixir.com/blog/tag/case-study) # Advancing Healthcare Decision-Making Through Network Meta-Analysis [![Clinixir](https://clinixir.com/hs-fs/hubfs/Clinixir_logo.png?width=40&height=40&name=Clinixir_logo.png)](https://clinixir.com/blog/author/admin) by Clinixir 2 min read May 30, 2025, 2:38:19 PM ## Clinixir's HEOR Services: Expert NMA Solutions in Oncology At Clinixir, we offer sophisticated Network Meta-Analysis (NMA) modeling as a core component of our Health Economics and Outcomes Research (HEOR) services. Our recent internal workshop in Lung Cancer Pharmacological Treatment demonstrates our commitment to delivering high-quality evidence synthesis for healthcare decision-makers. ![Clinix\_Service\_Sponsor’s](https://clinixir.com/hs-fs/hubfs/Image%20Stock/Clinix_Service_Sponsor%E2%80%99s.png?width=2000&height=807&name=Clinix_Service_Sponsor%E2%80%99s.png) ### What Our NMA Expertise Delivers: #### Comprehensive Evidence Synthesis Our advanced NMA methodologies allow for comparing multiple interventions simultaneously, even when they haven't been directly compared in clinical trials. Comprehensive Evidence Synthesis #### Personalized Treatment Insights Our analysts can stratify results by relevant biomarkers and patient characteristics, enabling more precise treatment recommendations. Personalized Treatment Insights #### Robust Statistical Frameworks We employ cutting-edge statistical techniques to ensure reliable, reproducible, and clinically relevant outcomes. Robust Statistical Frameworks ## Case Study: Immunotherapy in Advanced NSCLC Our recent workshop focused on comparing immunotherapy regimens for first-line treatment of advanced non-small cell lung cancer. The analysis: 1 #### Synthesized evidence from 6 Phase III randomized controlled trials involving over 3,000 patients Synthesized evidence 2 #### Evaluated treatments across different PD-L1 expression subgroups (\<1%, 1-49%, and ≥50%) Evaluated treatments 3 #### Identified optimal combinations for specific patient populations Identified optimal combinations 4 #### Aligned findings with regulatory approvals and clinical guidelines Aligned findings ### Key Insights from Our Analysis: PD-1 inhibitor combinations with chemotherapy demonstrated significant overall survival benefits compared to chemotherapy alone in the overall patient population  **For patients with PD-L1 expression 1-49%,** certain immunotherapy-chemotherapy combinations showed particularly strong survival benefits (HR = 0.52-0.61)  **For patients with PD-L1 expression ≥50%,** a dual immunotherapy approach yielded the most promising results (HR = 0.47) Stratification by biomarker status revealed critical differences in treatment efficacy, highlighting the importance of personalized treatment selection ### Visualizing Our NMA Methodology and Results ![image 6](https://clinixir.com/hs-fs/hubfs/image%206.png?width=634&height=300&name=image%206.png) **Figure 1: Network Map of Available Comparisons:** *This network map illustrates the connections between treatment regimens in our analysis. Node size represents the number of studies for each regimen, while line width indicates the number of direct comparisons available.* ![image 7](https://clinixir.com/hs-fs/hubfs/image%207.png?width=700&height=952&name=image%207.png) **Figure 2: Comparative Efficacy by PD-L1 Expression:** *These league tables present hazard ratios with 95% credible intervals for overall survival across different PD-L1 expression levels. Values below 1.00 indicate improved survival benefit.* ### Our NMA Service Process: 1 #### Systematic Literature Review Comprehensive search strategy and rigorous study selection Systematic Literature Review 2 #### Statistical Analysis State-of-the-art NMA modeling with appropriate heterogeneity assessments Statistical Analysis 3 #### Clinical Interpretation Translation of statistical findings into actionable clinical insights Clinical Interpretation 4 #### Publication Support Expert medical writing for manuscripts, reports, and HTA submissions Publication Support ### Why Choose Clinixir for NMA Our multidisciplinary team combines expertise in clinical research, biostatistics, and medical writing to deliver insights that support formulary decisions, health technology assessments, and clinical practice guidelines. #### *" Network Meta-Analysis represents a powerful tool in the HEOR toolkit, allowing stakeholders to make evidence-based decisions even in the absence of head-to-head clinical trials."* #HEOR #NetworkMetaAnalysis #RealWorldEvidence #MarketAccess #EvidenceSynthesis [Request RFP Form](https://clinixir.com/contact-us/rfp) Share this [Share on X](https://x.com/intent/post?url=https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3-1&text=Advancing%20Healthcare%20Decision-Making%20Through%20Network%20Meta-Analysis) [Share on Facebook](https://www.facebook.com/sharer/sharer.php?u=https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3-1&t=Advancing%20Healthcare%20Decision-Making%20Through%20Network%20Meta-Analysis) [Share on LinkedIn](https://www.linkedin.com/shareArticle?mini=true&url=https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3-1&t=Advancing%20Healthcare%20Decision-Making%20Through%20Network%20Meta-Analysis) Previous story [← Progress Highlights: Phase II/III Immunotherapy Trial for Advanced Liver Cancer](https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3) ## You May Also Like These Related Stories [Progress Highlights: Phase II/III Immunotherapy Trial for Advanced Liver Cancer](https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3) ![](https://clinixir.com/hubfs/Edited%20Photos/Clinix_Home_01.png) [Case Study](https://clinixir.com/blog/tag/case-study) ### Progress Highlights: Phase II/III Immunotherapy Trial for Advanced Liver Cancer May 26, 2025, 11:14:05 AM 2 min read [Is Your EDC System Future-Proof?](https://clinixir.com/blog/is-your-edc-system-future-proof) ![](https://clinixir.com/hubfs/Herobanner/Clinix_Blog_04-Thumnail.png) [Research Updates](https://clinixir.com/blog/tag/research-updates) ### Is Your EDC System Future-Proof? May 23, 2025, 10:21:28 AM 4 min read [The Role of Site Management Organizations (SMOs) in Accelerating Clinical Trials in Thailand](https://clinixir.com/blog/the-role-of-site-management-organizations-smos-in-accelerating-clinical-trials-in-thailand) ![](https://clinixir.com/hubfs/Imported_Blog_Media/The-Role-of-Site-Management-Organizations-SMOs-in-Accelerating-Clinical-Trials-in-Thailand_v2.png) [Research Updates](https://clinixir.com/blog/tag/research-updates) ### The Role of Site Management Organizations (SMOs) in Accelerating Clinical Trials in Thailand May 20, 2025, 1:44:47 PM 4 min read ![CLX\_Logo-Default](https://clinixir.com/hs-fs/hubfs/Logo/CLX_Logo-Default.png?width=206&height=46&name=CLX_Logo-Default.png) [173/18 Asia Centre Building, 17th Floor S Sathorn Rd, Sathon, Bangkok 10120](https://maps.app.goo.gl/XbLGN49iWPSFS1J67) [Download Our Company Booklet](https://clinixir.com/hubfs/Clinixir%20E-Booklet%20-%2009.10.24%201.pdf)  [enquiries@clinixir.com](mailto:enquiries@clinixir.com) [02-163-6430](tel:%2002-163-6430)   02-163-6432 © Copyright 2026 Clinixir All rights reserved. [Privacy Policy](https://clinixir.com/privacy-policy-clinixir) [![Social 01](https://clinixir.com/hs-fs/hubfs/Social%2001.png?width=318&height=313&name=Social%2001.png)](https://www.linkedin.com/company/clinixir/?originalSubdomain=th) [![Social 02](https://clinixir.com/hs-fs/hubfs/Social%2002.png?width=318&height=313&name=Social%2002.png)](https://www.facebook.com/clinixirthailand/) [![Social 03](https://clinixir.com/hs-fs/hubfs/Social%2003.png?width=318&height=313&name=Social%2003.png)](mailto:enquiries@clinixir.com) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Clinixir", "url" : "https://clinixir.com/blog/author/admin" }, "dateModified" : "2025-06-02T09:48:48.527Z", "datePublished" : "2025-05-30T07:38:19.000Z", "headline" : "Advancing Healthcare Decision-Making Through Network Meta-Analysis", "image" : [ "https://clinixir.com/hubfs/Edited%20Photos/Clinix_Blog_03-Thumnail.png" ], "mainEntityOfPage" : { "@id" : "https://clinixir.com/blog/the-phases-of-a-clinical-trial-the-start-up-phase-3-1", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://clinixir.com/hubfs/CLX_Logo-Default.png" }, "name" : "Clinixir" } } ```